Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00140504
Status:
COMPLETED
Last Update Posted:
2013-02-26
First Post:
2005-08-30
Brief Title:
Preventing Adverse Drug Events With PatientSite
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
05-061
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Saul N Weingart MD PhD
Responsible Party Title:
VP for Quality Improvement and Patient Safety
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Beth Israel Deaconess Medical Center | OTHER |
| Agency for Healthcare Research and Quality AHRQ | FED |
| Blue Cross Blue Shield | OTHER |